NBC 10 WJAR profiles Katie Brandt
April 1, 2025 Katie Brandt, Director of Caregiver Support Services and Public Relations at the MGH FTD Unit, shared her family’s connection to FTD and advice for caregivers on [...]
From Care to Cure episode 2 now available
March 20, 2025 The second episode of From Care to Cure, a podcast from the Massachusetts General Hospital Frontotemporal Disorders Unit, is available now. This episode features an interview with [...]
Katie Brandt announced as keynote speaker for 2025 AFTD Education Conference
March 5, 2025 AFTD is honored to welcome Katie Brandt, Director of MGH FTD Unit Caregiver Support Services and Public Relations, as the Keynote Speaker for its 2025 Education Conference. A [...]
A major milestone: one year of experience using lecanemab at MGH
March 4, 2025 At MGH we reached a milestone on March 4, 2025: one year of being able to administer lecanemab, the first new amyloid-lowering therapy for patients with early-stage Alzheimer’s [...]
From Care to Cure episode 1 now available
February 20, 2025 The first episode of From Care to Cure, a podcast from the Massachusetts General Hospital Frontotemporal Disorders Unit, is available now. This episode features an interview [...]
MGH FTD Unit Launches From Care to Cure Podcast
The MGH FTD Unit is excited to share that we are launching From Care to Cure, a podcast exploring care for a life lived with frontotemporal disorders, Alzheimer’s disease and related [...]
Care Plan Trifecta Webinar Series
February 11, 2025 Do you have questions about care planning after an FTD diagnosis? The MGH FTD Unit is excited to offer a four part webinar series about the Care Plan Trifecta (CPT), a framework [...]
FTD Unit team members presented new research at the Human Amyloid Imaging meeting
January 15, 2025 (San Juan, Puerto Rico) Our team members attended the Human Amyloid Imaging meeting that highlights cutting edge research on molecular imaging and other biomarkers of AD, FTD, [...]
New national medical guidelines for the diagnostic evaluation of patients suspected of having AD, FTD, or a related condition
December 23, 2024 We have entered a new era of improved and emerging biologically-based diagnostic biomarkers for Alzheimer’s disease (AD) and AD-related neurodegenerative disorders (ADRD) that [...]